Author

P. Lagarias

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Biophysics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:protein structure prediction· 1 Assay:structural biology· 1 Organism:virus· 1

Frequent Co-Authors

A. Kolocouris· 3 shared C. Ma· 2 shared J. A. Townsend· 2 shared J. Wang· 2 shared M. T. Marty· 2 shared Y. Hu· 2 shared A. Gao· 1 shared B. Hurst· 1 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiophysics

A. Kolocouris

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L

M. D. Sacco, C. Ma, P. Lagarias, A. Gao, J. A. Townsend, X. Meng, P. Dube, X. Zhang, Y. Hu, N. Kitamura, B. Hurst, B. Tarbet, M. T. Marty, A. Kolocouris, Y. Xiang, , J. Wang

This study determines the structure of SARS-CoV-2 Mpro with calpain inhibitors and analogues, revealing new insights for developing dual inhibitors against Mpro and cathepsin L.

Science Advances · Dec 11, 2020Peer-reviewedBiophysics

Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors

C. Ma, Y. Hu, J. A. Townsend, P. Lagarias, M. T. Marty, A. Kolocouris, J. Wang

This study shows that six compounds inhibit SARS-CoV-2 Mpro non-specifically and their antiviral activity cannot be predicted by IC50 values in the absence of DTT.

bioRxiv · Sep 15, 2020Biochemistry

Pharmacological Characterisation of Novel Adenosine Receptor A3R Antagonists

K. Barkan, P. Lagarias, M. Stampelou, D. Stamatis, S. Hoare, K.-N. Klotz, E. Vrontaki, A. Kolocouris, G. Ladds

This study characterizes a selective A3R antagonist, K18, and identifies its binding mode through molecular dynamics simulations and mutagenesis.

bioRxiv · Apr 28, 2020Pharmacology & Toxicology